Menu
Menu
There has been emerging evidence for the efficacy of ketamine used within the framework of psychotherapy, known as ketamine assisted psychotherapy. However, there are large differences between ketamine “clinics” and ketamine-assisted psychotherapy which can be offered in a community-based therapy setting. In this recording, we’ll look at some of those differences and ways to further integrate KAP into therapy settings.
Ketamine is an FDA approved medication that has been used for anesthesia and pain relief in adults and children for many years. It has been researched and utilized off label for the treatment of depression, post-traumatic stress disorder, and other “treatment resistant” mental health disorders. Thus far it has shown promising results in treating mental health disorders in clinical research studies mostly looking at IV Ketamine infusion offered in clinic settings.
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1.25 hours CPD for points calculation by your association.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - New Models for Ketamine Assisted Psychotherapy (15.45 MB) | 21 Pages | Available after Purchase | |
| Text Document | Transcript (38.9 KB) | 14 Pages | Available after Purchase |
| Manual - New Models for Ketamine Assisted Psychotherapy - French (15.45 MB) | 21 Pages | Available after Purchase | |
| Text Document | Transcript - French (38.9 KB) | 14 Pages | Available after Purchase |
| Manual - New Models for Ketamine Assisted Psychotherapy - Italian (15.45 MB) | 21 Pages | Available after Purchase | |
| Text Document | Transcript - Italian (38.9 KB) | 14 Pages | Available after Purchase |
Seema Desai, MD, is a board-certified child, adolescent, and adult psychiatrist with a clinical interest in the intersection of spirituality and psychiatry. She integrates principles of mindfulness into her work with patients and teaches mindfulness and mental health. She has a been a study therapist in research, examining the effects of psilocybin for the treatment of depressive disorder and existential anxiety related to end-stage cancer diagnosis. She is currently a study therapist in a MAPS trial examining the effects of MDMA for the treatment of PTSD. She offers psychopharmacology treatment and ketamine-assisted psychotherapy in her private practice. She is an assistant trainer with Fluence. For 10 years, she has served as assistant clinical professor of psychiatry at NYU School of Medicine and the NYU World Trade Center Health Program treating 9/11 first responders. She co-edited a book published by the American Psychiatric Association titled Becoming Mindful: Integrating Mindfulness into Your Psychiatric Practice.
Speaker Disclosures:
Financial: Dr. Seema Desai maintains a private practice and has employment relationships with New York University, MAPS New York Private Practice Site, and Fluence Training. She receives a speaking honorarium from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Seema Desai has no relevant non-financial relationships.
Please wait ...